Detalhe da pesquisa
1.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37308117
2.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35714673
3.
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
Cancer
; 127(6): 894-904, 2021 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33231866
4.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
J Natl Compr Canc Netw
; 19(5): 484-493, 2021 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34794122
5.
Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral blood mononuclear cells.
Mol Carcinog
; 59(10): 1129-1139, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32822091
6.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(4): 452-478, 2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32259783
7.
Adaptive Randomization of Neratinib in Early Breast Cancer.
N Engl J Med
; 375(1): 11-22, 2016 Jul 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27406346
8.
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
N Engl J Med
; 375(1): 23-34, 2016 Jul 07.
Artigo
Inglês
| MEDLINE | ID: mdl-27406347
9.
Male breast cancer: a disease distinct from female breast cancer.
Breast Cancer Res Treat
; 173(1): 37-48, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30267249
10.
NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
J Natl Compr Canc Netw
; 17(2): 118-126, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30787125
11.
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Breast Cancer Res
; 20(1): 82, 2018 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30071865
12.
NCCN Guidelines Updates: Breast Cancer.
J Natl Compr Canc Netw
; 16(5S): 605-610, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29784737
13.
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(3): 310-320, 2018 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-29523670
14.
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Lancet
; 388(10043): 488-97, 2016 Jul 30.
Artigo
Inglês
| MEDLINE | ID: mdl-27291997
15.
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
J Natl Compr Canc Netw
; 15(4): 433-451, 2017 04.
Artigo
Inglês
| MEDLINE | ID: mdl-28404755
16.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 14(3): 324-54, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26957618
17.
Breast Cancer Following Radiation for Hodgkin Lymphoma: Clinical Scenarios and Risk-Reducing Strategies.
Oncology (Williston Park)
; 30(12): 1063-70, 2016 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27987198
18.
NCCN Guidelines Insights Breast Cancer, Version 1.2016.
J Natl Compr Canc Netw
; 13(12): 1475-85, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26656517
19.
Breast Cancer Version 2.2015.
J Natl Compr Canc Netw
; 13(4): 448-75, 2015 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-25870381
20.
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
Breast Cancer Res
; 16(1): R7, 2014 Jan 22.
Artigo
Inglês
| MEDLINE | ID: mdl-24451109